



Dr. med. Dominik Zieglgänsberger

Neurologie · Dept. III

Kontakt

Dr. med. Dominik Zieglgänsberger
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 1663
Dominik.Zieglgaensberger@kssg.ch

Bereiche

Neurologie

Publikationen (15)

Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. *J Neurol* 2024

Johannesen K, Nielsen J, Sabers A, Isidor B, Kattentidt-Mouravieva A, Zieglgänsberger D, Heidlebaugh A, Oetjens K, Vidal A, Christensen J, Tiller J, Freed A, Møller R, Rubboli G. The phenotypic presentation of adult individuals with SCL6A1-related neurodevelopmental disorders. *Front Neurosci* 2023; 17:1216653.

Sinka L, Abaira L, Imbach L, Zieglgänsberger D, Santamarina E, Álvarez-Sabín J, Ferreira-Atuesta C, Katan M, Scherrer N, Biciato G, Terziev R, Simmen C, Schubert K, Elshahabi A, Baumann C, Döhler N, Erdélyi-Canavese B, Felbecker A, Siebel P, Winklehner M, von Oertzen T, Wagner J, Gigli G, Serafini A, Nilo A, Janes F, Merlino G, Valente M, Zafra-Sierra M, Bayona-Ortiz H, Conrad J, Evers S, Lochner P, Roell F, Brigo F, Bentes C, Peralta A, Pinho E Melo T, Keezer M, Duncan J, Sander J, Tettenborn B, Koepp M, Galovic M. Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model. *JAMA Neurol* 2023; 80:605-613.

Zieglgänsberger D, Broser P. Epilepsie - Grundsätze der medikamentösen Therapie. In *FO NEUROLOGIE & PSYCHIATRIE* 2018 2018; Vol. 16

Zieglgänsberger D, Flügel D. [New anticonvulsants in everyday clinical use]. *Ther Umsch* 2018; 75:444-447.

Walch J, Prochnicki A, Zieglgänsberger D, Hägele-Link S, Tettenborn B, Hader C, Weber J, Heilbronner R (2016). Acute clinical deterioration of a patient with spinal dural arteriovenous malformation after lumbar puncture and steroid treatment – a case report and discussion of possible reasons.

Leupold D, Schilg-Hafer L, Felbecker A, Zieglgänsberger D, Tettenborn B, Hundsberger T (2016). Chronic inflammatory demyelinating polyneuropathy – still a challenging diagnosis.

Zieglgänsberger D. Grundsätze der medikamentösen Therapie bei Epilepsie im Erwachsenenalter. *INFO Neurologie und Psychiatrie* 2016; 3:8-11.

Zieglgänsberger D, Tettenborn B. Anticonvulsive Therapy after the First Unprovoked Seizure – Pros and Cons. *Praxis (Bern 1994)* 2016; 105:41-5.

Leupold D, Schilg-Hafer L, Felbecker A, Zieglgänsberger D, Tettenborn B, Hundsberger T (2015). Chronic inflammatory demyelinating polyneuropathy- still a challenging diagnosis.

Prochnicki A, Zieglgänsberger D, Vehoff J, Müller S, Tettenborn B, Hundsberger T (2015). Glioblastoma multiforme: Chameleon of neurology A case report.

Scherrer M, Zieglgänsberger D, Tettenborn B (2014). Valproate-induced Parkinsonism in Epilepsy Patient.

Zieglgänsberger D, Vehoff J, Hägele-Link S, Tettenborn B (2013). Aseptische Myelitis durch Fremdkörperreaktion bei intrathekalem Opioid-Katheter – 2 Fälle.

Zieglänsberger D, Hägele-Link S, Tettenborn B (2013). Hypothenar-Hammer-Syndrom bei schwerer Kamptokormie bei M.Parkinson.

Ott I, Andrassy M, Zieglänsberger D, Geith S, Schömig A, Neumann F. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood 2001; 97:3721-6.

Projekte (2)

Swiss Primary Hypersomnolence and Narcolepsy Cohort Study

Klinische Forschung - 01.01.2021 - 31.12.2023

Abgeschlossen

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention (ARISE-Study)

Klinische Forschung - 01.06.2015 - 31.12.2017

Automatisch geschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch